Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million.
Vinge’s team has primarily consisted of Dain Hård Nevonen, Linnéa Sellström, Anna Svensson and Michaela Ådén (Capital Markets and Public M&A) as well as Victor Ericsson, Emelie Svanberg and Erik Kochbati (Corporate Tax).
